Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks
Executive Summary
PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.
You may also be interested in...
Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant
With a leadership position in the US generics association and a new CEO focused on how to reallocate resources, Teva leaves the brand trade association after a review of the ‘effectiveness and value of engagements.’
At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
PhRMA Adds Genentech, Gilead To Its Ranks Ahead Of House Democrats’ Drug Pricing Scrutiny
Roche, through Genentech, returns to the PhRMA fold after leaving the trade group in 2009; Gilead is a first-time member; both are retaining their BIO memberships as well.